280 Utah Avenue
South San Francisco
About Annexon Biosciences
Annexon Biosciences is leading the development of therapeutic products that halt the progression of CMND. Our antibody pipeline is based on breakthrough research involving the classical complement pathway and the unique role of its initiating molecule, C1q, in triggering the loss of nerve connections and inducing inflammation in neurologic and ophthalmic disorders.
CEO: Douglas Love, Esq
Chief Scientific Officer: Ted Yednock, PhD
Chief Medical Officer: Mario Saltarelli, MD, PhD
10 articles with Annexon Biosciences
Intravitreal ANX007 was well-tolerated and demonstrated full target engagement and inhibition of C1q in the eye for at least four weeks
Annexon Biosciences Reports Top-line Phase 1b Results for Novel C1q Inhibitor ANX005 in Guillain-Barré Syndrome
Annexon Biosciences announced encouraging results from a Phase 1b dose-ranging clinical trial to evaluate its anti-C1q antibody, ANX005.
Annexon Biosciences Announces FDA Fast Track Designation for Novel C1q Inhibitor ANX005 for the Treatment of Guillain-Barré Syndrome
Annexon plans to advance the clinical development of ANX005 for the treatment of GBS
7/12/2019Biotech and pharma companies strengthen their leadership teams with new appointments.
Annexon Biosciences Expands Senior Leadership as it Advances its Novel Complement Approach to Autoimmune and Neurodegenerative Disorders
Sanjay Keswani, MBBS, BSc, FRCP, Chief Medical Officer Jennifer Lew, Chief Financial Officer Lesley Stolz, PhD, Chief Business Officer
With the holiday upon us, many companies in the pharma and biotech industry have made some important announcements – some big, some small. BioSpace has gathered a number of announcements that might have gone unnoticed and put them together below.
Annexon Biosciences, a clinical stage biopharmaceutical company focused on the development of novel therapeutics through inhibition of the classical complement pathway, today announced that it has closed a $75 million Series C financing.
Bioasis Further Strengthens Scientific Advisory Board with Addition of Dr. Mario Saltarelli, Dr. Jack Hoppin and Dr. Sue O’Connor
BIOASIS TECHNOLOGIES INC. today announced the addition of Mario Saltarelli, M.D., Ph.D., Jack Hoppin, Ph.D. and Sue O’Connor, B.Sc. (Hons), Ph.D. to its scientific advisory board.